Latest News and Press Releases
Want to stay updated on the latest news?
-
$3.3M in revenue representing 108% Y-Y growth, significant growth in finished product sales Total of 4 brands, 16 SKU’s and 35 “cannabis 2.0” listings across medical and retail...
-
NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. ANY FAILURE TO COMPLY WITH THIS RESTRICTION MAY CONSTITUTE A VIOLATION OF UNITED STATES SECURITIES...
-
TORONTO, Feb. 14, 2022 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or the “Company”) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), an innovative, commercial-stage, and international biopharmaceutical...
-
TORONTO, Feb. 02, 2022 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or the “Company “) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), an innovative, commercial-stage, and international biopharmaceutical...
-
NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. ANY FAILURE TO COMPLY WITH THIS RESTRICTION MAY CONSTITUTE A VIOLATION OF UNITED STATES SECURITIES...
-
Expansion and fortification of relationship since 2020 with established pharmaceutical company in Chile Supply of Avicanna’s active pharmaceutical ingredients for existing commercial and pipeline...
-
TORONTO, Jan. 10, 2022 (GLOBE NEWSWIRE) -- Avicanna USA Inc. together with Avicanna Inc. ("Avicanna" or the "Company") (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a biopharmaceutical company focused on...
-
TORONTO, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or the “Company“) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a biopharmaceutical company focused on the development, manufacturing...
-
First commercial export of Cannabigerol (CBG), a rare cannabinoid, into Czech Republic This export represents the 14th international market entrance for Avicanna products TORONTO, Dec. 24, 2021 ...
-
The THC-Free, CBD derma-cosmetic brand is the first known CBD skincare line to be clinically tested and commercialized across four international markets The initial launch of Pura H&W will...